Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

• Main Authors: Andrew Hill (Author), Dzintars Gotham (Author), Graham Cooke (Author), Sanjay Bhagani (Author), Isabelle Andrieux-Meyer (Author), Jennifer Cohn (Author), Joseph Fortunak (Author)
• Format: Bog
• Udgivet: Elsevier, 2015-04-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

Background: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass treatment programmes for hepatitis B will require very low drug costs. International treatment guidelines recommend first-line monotherapy with either entecavir or tenofovir disoproxil fumara...